May 22, 2008 by Brian Orelli, PhDWyeth's Never-Ending Generic WoesNovartis jumps on the generic Protonix bandwagon.
May 22, 2008 by Brian Orelli, PhDMerck Can't ACHIEVE AnythingThe pharmaceutical cancels a troubled clinical trial.
May 21, 2008 by Brian Orelli, PhDOK, Last Vioxx Settlement, Honest!What's another $58 million when Merck's already forking over $4.85 billion?
May 21, 2008 by Brian Orelli, PhDMedtronic's Endeavors Look GoodThe medical device maker's new drug-eluting stent helps push up revenue.
May 21, 2008 by Brian Orelli, PhDDr. Reddy Needs an Amnesia PillThe pharmaceutical's year-over-year comparison headache is finally over.
May 20, 2008 by Brian Orelli, PhDIs Google's Newest Offering a Healthy Investment?Having all your medical records in one place is a good idea, but will people use it?
May 19, 2008 by Brian Orelli, PhDWhat Will Icahn Do With Amylin?Sell or advocate for management changes seems to be his M.O.
May 15, 2008 by Brian Orelli, PhDWanted: FDA Approval -- ProntoTeva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.
May 15, 2008 by Brian Orelli, PhDSo-So SyneronA little growth is an acceptable outcome in a struggling industry.
May 14, 2008 by Brian Orelli, PhDAbbott Knocks Down Boston ScientificHead-to-head trials are so much fun ... for the winner.
May 14, 2008 by Brian Orelli, PhDA BABY's Got to GrowA secondary stock offering that investors should be happy about.
May 13, 2008 by Brian Orelli, PhDOmrix's Wild RideRevenue growth is most important for high-growth companies.
May 13, 2008 by Brian Orelli, PhDIs Merck Keeping Its Enemies Close?The drugmaker strikes a deal with an Indian generic company.
May 12, 2008 by Brian Orelli, PhDAOB Is A-OKExtrinsic growth helps American Oriental Bioengineering build a mighty fine quarter.
May 7, 2008 by Brian Orelli, PhDBlack Onyx, but Not for LongOnyx posts a stellar quarter, but earnings are headed in the other direction for the rest of the year.
